Travere Corp (TVTX) - מקדם חוב לטווח ארוך להון

Travere Therapeutics (TVTX) risks facing supply chain disruptions from Asia due to political conflicts. At the same time, the business relies on unique developments for treating kidney pathologies that ensure monopoly income. Innovations are focused on the implementation of the safe Filspari therapy. The indicator stands at 23.33, which is visualized in the company's current share price shown on this chart.

To filter for high-quality assets, investors evaluate the level of financial leverage via the ratio of liabilities with a maturity of over one year to equity. This long-term capital structure metric determines the extent of Travere Therapeutics (TVTX) dependence on borrowed funds to finance the development of Filspari, demonstrating the balance between debt load and the capital base required to protect exclusive rights to orphan drugs.